AbstractMatched unrelated donor (MUD) transplantation is the first alternative in the absence of a matched sibling donor. For patients without a suitable adult donor, we have adopted the dual stem cell transplantation protocol consisting of cord blood (CB) in combination with CD34+ cells from a third party HLA-mismatched donor. We analyzed the outcomes of patients undergoing both procedures in a single center. Starting in 2004, a total of 20 patients with high-risk disease underwent 22 dual transplants and 25 patients underwent myeloablative MUD transplantation. The 30-day cumulative incidence of neutrophil engraftment was similar in both groups (91% and 95%), with a median time to engraftment of 14 and 16 days, respectively. Grade II-IV ac...
The potential benefits of unrelated donor bone marrow transplantation are offset by the immunologic ...
BackgroundPatients with severe combined immunodeficiency disease who have matched sibling donors (MS...
AbstractSince January 1996, we have administered myeloablative therapy followed by infusion of unrel...
AbstractMatched unrelated donor (MUD) transplantation is the first alternative in the absence of a m...
Cord blood transplantation (CB-T) is increasingly used as a treatment alternative for hematologic ma...
AbstractHematopoietic stem cell transplantation (HSCT) remains the only curative treatment in patien...
The optimal alternative donor for adult hematopoietic stem cell transplantation (HSCT) candidates wh...
The donor selection algorithm for cord blood (CB) with regards to matched related and unrelated dono...
To determine whether the risks of allogeneic transplantation are different when the donor is a fully...
Recent advances in unrelated cord blood transplantation (UCBT) and high-resolution typing of human l...
AbstractTwo parallel phase II trials in adults with hematologic malignancies demonstrated comparable...
Most candidates for hematopoietic stem cell transplantation (HSCT) lack a human leukocyte antigen (H...
[Background.] Unrelated cord blood (UCB) and haploidentical related donor transplantation using post...
AbstractUmbilical cord blood (UBC) stem cells are a useful stem cell source for patients without mat...
AbstractAmong the strategies to optimize engraftment of cord blood (CB) stem cell transplantation (S...
The potential benefits of unrelated donor bone marrow transplantation are offset by the immunologic ...
BackgroundPatients with severe combined immunodeficiency disease who have matched sibling donors (MS...
AbstractSince January 1996, we have administered myeloablative therapy followed by infusion of unrel...
AbstractMatched unrelated donor (MUD) transplantation is the first alternative in the absence of a m...
Cord blood transplantation (CB-T) is increasingly used as a treatment alternative for hematologic ma...
AbstractHematopoietic stem cell transplantation (HSCT) remains the only curative treatment in patien...
The optimal alternative donor for adult hematopoietic stem cell transplantation (HSCT) candidates wh...
The donor selection algorithm for cord blood (CB) with regards to matched related and unrelated dono...
To determine whether the risks of allogeneic transplantation are different when the donor is a fully...
Recent advances in unrelated cord blood transplantation (UCBT) and high-resolution typing of human l...
AbstractTwo parallel phase II trials in adults with hematologic malignancies demonstrated comparable...
Most candidates for hematopoietic stem cell transplantation (HSCT) lack a human leukocyte antigen (H...
[Background.] Unrelated cord blood (UCB) and haploidentical related donor transplantation using post...
AbstractUmbilical cord blood (UBC) stem cells are a useful stem cell source for patients without mat...
AbstractAmong the strategies to optimize engraftment of cord blood (CB) stem cell transplantation (S...
The potential benefits of unrelated donor bone marrow transplantation are offset by the immunologic ...
BackgroundPatients with severe combined immunodeficiency disease who have matched sibling donors (MS...
AbstractSince January 1996, we have administered myeloablative therapy followed by infusion of unrel...